A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors
Latest Information Update: 08 Oct 2025
At a glance
- Drugs YL-202 (Primary)
- Indications Cervical cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors MediLink Therapeutics
Most Recent Events
- 08 Oct 2025 New trial record